Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: A review and position statement by the European Organisation for Research and Treatment of Cancer imaging group

European Journal of Cancer

Volumn 50, Issue 15, 2014, Pages 2519-2531

  Lecouvet, F E ^a,g   Talbot, J N ^b   Messiou, C ^c   Bourguet, P ^d   Liu, Y ^e   De Souza, N M ^c,f  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b HÔPITAL TENON   (France)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d CENTRE EUGÈNE MARQUIS   (France)

^e Molecular Imaging and Experimental Radiotherapy Department   (Belgium)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Bone; Cancer; EORTC; Imaging; Metastases; MRI; PET; RECIST; Response; Treatment

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

BONE NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; HUMAN; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY; SECONDARY; SENSITIVITY AND SPECIFICITY;

BONE NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84907441450     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.07.002     Document Type: Article

References (109)

1. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
2. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
3. F. Saad, J.A. Eastham, and M.R. Smith Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer Urologic Oncol 30 2012 369 378
4. J.P. O'Connor, A. Jackson, G.J. Parker, and G.C. Jayson DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents Br J Cancer 96 2007 189 195
5. E.M. Charles-Edwards, and N.M. de Souza Diffusion-weighted magnetic resonance imaging and its application to cancer Cancer Imag 6 2006 135 143
6. A.R. Padhani, and K.A. Miles Multiparametric imaging of tumor response to therapy Radiology 256 2010 348 364
7. V.N. Harry, S.I. Semple, D.E. Parkin, and F.J. Gilbert Use of new imaging techniques to predict tumour response to therapy Lancet Oncol 11 2010 92 102
8. L. Heijmen, M.C. Verstappen, and E.E. Ter Voert Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use? Crit Rev Oncol/Hematol 83 2012 194 207
9. A. Biffar, S. Sourbron, and G. Schmidt Measurement of perfusion and permeability from dynamic contrast-enhanced MRI in normal and pathological vertebral bone marrow Magn Reson Med 64 2010 115 124
10. S. Biswal, D.L. Resnick, J.M. Hoffman, and S.S. Gambhir Molecular imaging: integration of molecular imaging into the musculoskeletal imaging practice Radiology 244 2007 651 671
11. H.E. Daldrup-Link, T. Henning, and T.M. Link MR imaging of therapy-induced changes of bone marrow Eur Radiol 17 2007 743 761
12. F.E. Lecouvet, A. Larbi, and V. Pasoglou MRI for response assessment in metastatic bone disease Eur Radiol 23 2013 1986 1997
13. C. Messiou, G. Cook, and N.M. de Souza Imaging metastatic bone disease from carcinoma of the prostate Br J Cancer 101 2009 1225 1232
14. C. Messiou, D.J. Collins, V.A. Morgan, D. Bianchini, J.S. de Bono, and N.M. de Souza Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values Skeletal Radiol 43 2014 205 208
15. T. Pearce, S. Philip, J. Brown, D.M. Koh, and P.R. Burn Bone metastases from prostate, breast and multiple myeloma: differences in lesion conspicuity at short-tau inversion recovery and diffusion-weighted MRI Br J Radiol 85 2012 1102 1106
16. F.E. Lecouvet, M. Simon, B. Tombal, J. Jamart, B.C. Vande Berg, and P. Simoni Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa) Eur Radiol 20 2010 2973 2982
17. F.E. Lecouvet, D. Geukens, and A. Stainier Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies J Clin Oncol 25 2007 3281 3287
18. C. Messiou, and N.M. de Souza Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring Cancer Biomarkers 6 2010 21 32
19. S. Bonekamp, C.P. Corona-Villalobos, and I.R. Kamel Oncologic applications of diffusion-weighted MRI in the body J Magn Reson Imag 35 2012 257 279
20. C. Messiou, D.J. Collins, S. Giles, J.S. de Bono, D. Bianchini, and N.M. de Souza Assessing response in bone metastases in prostate cancer with diffusion weighted MRI Eur Radiol 21 2011 2169 2177
21. L.M. Wu, H.Y. Gu, and J. Zheng Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis J Magn Reson Imaging 34 2011 128 135
22. F.E. Lecouvet, B.C. Vande Berg, J. Malghem, P. Omoumi, and P. Simoni Diffusion-weighted MR imaging: adjunct or alternative to T1-weighted MR imaging for prostate carcinoma bone metastases? Radiology 252 2009 624
23. M. Eiber, T. Takei, and M. Souvatzoglou Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions J Nucl Med 55 2 2014 191 197
24. H.M. Linden, S.A. Stekhova, and J.M. Link Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer J Clin Oncol 24 18 2006 2793 2799
25. M.L. Gemignani, S. Patil, and V.E. Seshan Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer J Nucl Med 54 10 2013 1697 1702
26. M. van Kruchten, A.W. Glaudemans, and E.F. de Vries PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma J Nucl Med 53 2 2012 182 190
27. S.M. Larson, M. Morris, and I. Gunther Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer J Nucl Med 45 3 2004 366 373
28. 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer Eur J Nucl Med Mol Imag 41 1 2014 11 20
29. E. Kähkönen, I. Jambor, and J. Kemppainen In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548 Clin Cancer Res 19 19 2013 5434 5443
30. X. Ndlovu, R. George, A. Ellmann, and J. Warwick Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun 31 2010 659 665
31. P. Sharma, H. Singh, and R. Kumar Bone scintigraphy in breast cancer: added value of hybrid SPECT-CT and its impact on patient management Nucl Med Commun 33 2012 139 147
32. J.N. Talbot, F. Paycha, and S. Balogova Diagnosis of bone metastasis: recent comparative studies of imaging modalities Q J Nucl Med Mol Imag 55 2011 374 410
33. Y. Zhang, H. Shi, and D. Cheng Added value of SPECT/spiral CT versus SPECT in diagnosing solitary spinal lesions in patients with extraskeletal malignancies Nucl Med Commun 34 2013 451 458
34. 18FDG PET, CT, MRI and bone scintigraphy Eur Radiol 21 2011 2604 2617
35. V. Helyar, H.K. Mohan, and T. Barwick The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate Eur J Nucl Med Mol Imag 37 2010 706 713
36. D. Chakraborty, A. Bhattacharya, U.K. Mete, and B.R. Mittal Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma Clin Nucl Med 38 2013 616 621
37. E. Even-Sapir, U. Metser, E. Mishani, G. Lievshitz, H. Lerman, and I. Leibovitch The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT J Nucl Med 47 2006 287 297
38. M. Hetzel, C. Arslandemir, and H.H. Konig F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management J Bone Miner Res 18 2003 2206 2214
39. 18F]fluoro-2-deoxy-d-glucose (FDP-PET scanning) in oncology (2002) Br J Cancer 89 Suppl. 1 2003 S84 S91
40. L. Evangelista, A. Panunzio, and R. Polverosi Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging Biomed Pharmacother 66 2012 448 453
41. 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia Am J Hematol 86 7 2011 567 572
42. 18F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients J Nucl Med 53 2012 1730 1735
43. 99mTc-MDP bone scan Jpn J Radiol 31 2013 262 269
44. 18F-FDG PET/CT Eur J Nucl Med Mol Imag 36 2009 1807 1812
45. W. Langsteger, S. Balogova, and V. Huchet Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading Q J Nucl Med Mol Imag 55 2011 448 457
46. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type Eur J Nucl Med Mol Imag 40 2013 943 966
47. C.M. Costelloe, V. Kundra, and J. Ma Fast Dixon whole-body MRI for detecting distant cancer metastasis: a preliminary clinical study J Magn Reson Imaging 35 2012 399 408
48. N. Ghanem, C. Altehoefer, and S. Hogerle Comparative diagnostic value and therapeutic relevance of magnetic resonance imaging and bone marrow scintigraphy in patients with metastatic solid tumors of the axial skeleton Eur J Radiol 43 2002 256 261
49. A.L. Brown, G. Middleton, A.D. MacVicar, and J.E. Husband T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy Clin Radiol 53 1998 493 501
50. P. Saip, N. Tenekeci, and A. Aydiner Response evaluation of bone metastases in breast cancer: value of magnetic resonance imaging Cancer Invest 17 1999 575 580
51. I. Ciray, H. Lindman, K.G. Astrom, J. Bergh, and K.H. Ahlstrom Early response of breast cancer bone metastases to chemotherapy evaluated with MR imaging Acta Radiol 42 2001 198 206
52. B. Tombal, A. Rezazadeh, P. Therasse, P.J. Van Cangh, B. Vande Berg, and F.E. Lecouvet Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases Prostate 65 2005 178 187
53. T.J. Graham, G. Box, N. Tunariu, M. Crespo, T.J. Spinks, and S. Miranda Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib J Natl Cancer Inst 106 2014 dju033
54. K.C. Lee, S. Sud, and C.R. Meyer An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone Cancer Res 67 2007 3524 3528
55. S. Rozel, C.J. Galban, and K. Nicolay Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model J Cell Biochem 107 2009 58 64
56. T. Bauerle, S. Bartling, and M. Berger Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis Eur J Radiol 73 2010 280 287
57. C. Reischauer, J.M. Froehlich, and D.M. Koh Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps - initial observations Radiology 257 2010 523 531
58. 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma J Nucl Med 54 7 2013 Jul 1053 1059
59. M.D. Blackledge, D.J. Collins, N. Tunariu, M.R. Orton, A.R. Padhani, and M.O. Leach Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study PLoS ONE 9 2014 e91779
60. F. Montemurro, F. Russo, and L. Martincich Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy Acta Radiol 45 2004 71 74
61. M.D. Budde, E. Gold, E.K. Jordan, and J.A. Frank Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI Clin Exp Metastasis 29 2012 51 62
62. V. Vassiliou, and D. Andreopoulos Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria Br J Cancer 103 2010 925 926 [author reply 7]
63. K.C. Lee, D.A. Bradley, and M. Hussain A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone Neoplasia 9 2007 1003 1011
64. A.R. Padhani, A. Makris, P. Gall, D.J. Collins, N. Tunariu, and J.S. DeBono Therapy monitoring of skeletal metastases with whole-body diffusion MRI J Magn Reson Imaging 39 5 2014 1049 1078
65. R. Coleman, M. Gnant, G. Morgan, and P. Clezardin Effects of bone-targeted agents on cancer progression and mortality J Natl Cancer Inst 104 2012 1059 1067
66. L.S. Rosen, D. Gordon, and S. Tchekmedyian Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 2003 3150 3157
67. Y. Mitsui, H. Shiina, and Y. Yamamoto Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer BJU Int 110 2012 E628 E634
68. M.S. Brown, G.H. Chu, and H.J. Kim Computer-aided quantitative bone scan assessment of prostate cancer treatment response Nucl Med Commun 33 2012 384 394
69. R.E. Coleman, G. Mashiter, K.B. Whitaker, D.W. Moss, R.D. Rubens, and I. Fogelman Bone scan flare predicts successful systemic therapy for bone metastases J Nucl Med 29 1988 1354 1359
70. R.E. Coleman, G. Mashiter, I. Fogelman, K.D. Whitaker, M. Caleffi, and D.W. Moss Osteocalcin: a potential marker of metastatic bone disease and response to treatment Eur J Cancer Clin Oncol 24 1988 1211 1217
71. H.I. Scher, and A. Yagoda Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors Am J Med 82 1987 6 28
72. R.E. Coleman, K.B. Whitaker, D.W. Moss, G. Mashiter, I. Fogelman, and R.D. Rubens Biochemical prediction of response of bone metastases to treatment Br J Cancer 58 1988 205 210
73. J.J. Pollen, K.F. Witztum, and W.L. Ashburn The flare phenomenon on radionuclide bone scan in metastatic prostate cancer AJR Am J Roentgenol 142 1984 773 776
74. C.J. Ryan, S. Shah, and E. Efstathiou Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response Clin Cancer Res 17 2011 4854 4861
75. J.H. DeMeo, J. Balseiro, and T.J. Cole Etidronate sodium therapy - a cause of poor skeletal radiopharmaceutical uptake Semin Nucl Med 21 1991 332 334
76. M.P. Roudier, H. Vesselle, and L.D. True Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results Clin Exp Metastasis 20 2003 171 180
77. 223Ra-chloride (Alpharadin) EJNMMI Res 2011 1 4
78. 18F-fluoride ion PET bone scanning AJR Am J Roentgenol 186 2006 1783 1786
79. J. Installe, A. Nzeusseu, A. Bol, G. Depresseux, J.P. Devogelaer, and M. Lonneux (18)F-fluoride PET for monitoring therapeutic response in Paget's disease of bone J Nucl Med 46 2005 1650 1658
80. 18F-fluoride uptake Clin Nucl Med 38 2013 200 202
81. 18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound Clin Nucl Med 38 2013 746 748
82. 18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy J Clin Oncol 24 2006 3026 3031
83. S.E. Stafford, J.R. Gralow, and E.K. Schubert Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy Acad Radiol 9 2002 913 921
84. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1999 1773 1782
85. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl. 1 2009 122S 150S
86. C.A. Thacker, G.J. Weiss, and R. Tibes 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib Cancer Med 1 2 2012 230 236
87. K. Skougaard, D. Nielsen, B.V. Jensen, and H.W. Hendel Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab J Nucl Med 54 7 2013 1026 1031
88. T. Katayama, K. Kubota, Y. Machida, A. Toriihara, and H. Shibuya Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers Ann Nucl Med 26 2012 426 435
89. V. Huyge, C. Garcia, and J. Alexiou Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients Clinl Oncol(R Coll Radiol) 22 10 2010 818 827
90. J.E. Mortimer, F. Dehdashti, B.A. Siegel, K. Trinkaus, J.A. Katzenellenbogen, and M.J. Welch Metabolic flare: indicator of hormone responsiveness in advanced breast cancer J Clin Oncol 19 2001 2797 2803
91. N. Mortazavi-Jehanno, A.L. Giraudet, and L. Champion Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study Eur J Nucl Med Mol Imag 39 2012 450 460
92. S. Balogova, J. Ben Zakoun, and L. Michaud FCH PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone - a pilot study Nuklearmedizin 52 6 2013 A124 A125
93. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy J Nucl Med 50 2009 1427 1434
94. I. Gordon, A.M. Peters, A. Gutman, S. Morony, C. Dicks-Mireaux, and J. Pritchard Skeletal assessment in neuroblastoma - the pitfalls of iodine-123-MIBG scans J Nucl Med 31 1990 129 134
95. L. Troncone, V. Rufini, P. Montemaggi, F.M. Danza, A. Lasorella, and R. Mastrangelo The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience Eur J Nucl Med 16 1990 325 335
96. T. Pfluger, C. Schmied, and U. Porn Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma AJR Am J Roentgenol 181 2003 1115 1124
97. S. Leboulleux, C. Dromain, and A.L. Vataire Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy J Clin Endocrinol Metabol 93 2008 3021 3028
98. R. Lebtahi, G. Cadiot, and N. Delahaye Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy J Nucl Med 40 1999 1602 1608
99. J.M. Zuetenhorst, C.A. Hoefnageli, H. Boot, R.A. Valdes Olmos, and B.G. Taal Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease Nucl Med Commun 23 2002 735 741
100. 18F-FDG) positron emission tomography J Natl Cancer Inst 104 2012 700 708
101. L.M. Kenny, R.C. Coombes, and I. Oulie Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients J Nucl Med 49 6 2008 879 886
102. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
103. J.J. Fox, M.J. Morris, S.M. Larson, H. Schöder, and H.I. Scher Developing imaging strategies for castration resistant prostate cancer Acta Oncol 50 Suppl. 1 2011 39 48
104. P.F. Mulders, and J.A. Schalken Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer Prostate Cancer Prostatic Dis 12 2009 241 246
105. J.M. Fitzpatrick, J. Bellmunt, and K. Fizazi Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel Eur J Cancer 50 2014 1617 1627
106. S.A. Kwee, T.R. De Grado, and J.N. Talbot Cancer imaging with fluorine-18-labeled choline derivatives Semin Nucl Med 37 6 2007 420 428
107. K.D. Linton, and J.W. Catto Whole-body magnetic resonance imaging and prostate cancer metastases: a new gold standard of detection, but does it help us and at what cost? Eur Urol 62 2012 76 77
108. C.M. Gaeta, J.L. Vercher-Conejero, A.C. Sher, A. Kohan, C. Rubbert, and N. Avril Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers Q J Nucl Med Mol Imag 57 2013 352 366
109. E. Ashton, and J. Riek Advanced MR techniques in multicenter clinical trials J Magn Reson Imaging 37 2013 761 769